Ulcerative Colitis

Older patients with inflammatory bowel disease who initiate Entyvio therapy had lower risk for hospitalization than those treated with anti-TNF, according to research presented at the Crohn’s and Colitis Congress.

A presenter at the Crohn’s and Colitis Congress highlighted the importance of biomarkers in determining disease activity in inflammatory bowel disease, especially in the era of COVID-19.

In this exclusive video, Anita Afzali, MD, director of the inflammatory bowel disease center at The Ohio State University, discusses the impact of emerging therapies in IBD.

Polygenic risk scores compiled using data from a multi-ethnic biobank helped improve predictions for inflammatory bowel disease, according to study results.

Healio Gastroenterology looks back at the Peer Tested content from online and print as it fared throughout the year and what made us stand out in 2020.

Over the last decade-plus, the introduction of several key therapies has shaped the management of inflammatory bowel disease.

In this exclusive video, Jessica Allegretti, MD, MPH, discussed the use of fecal microbiota transplantation to treat Clostridioides difficile infection in inflammatory bowel disease, IBD alone and to treat patients with J-pouches.

A recent study showed that cigarette smoking was associated with an increased risk for colorectal cancer. It was the top story in gastroenterology last week.

In this exclusive video, Miguel Regueiro, MD, from Cleveland Clinic, discusses the effort to hold the first virtual Advances in Inflammatory Bowel Diseases conference.

Abivax has completed enrollment in a phase 2b induction study for its ulcerative colitis drug candidate ABX464, according to a company press release.